Cel-Sci (LSR) AI Stock Analysis

Top Page

Cel-Sci

(Frankfurt:LSR)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Focused immunotherapy pipelineA focused immunotherapy program gives CEL-SCI a clear strategic direction and the potential to build specialized expertise around immune-system activation in cancer. If clinical development succeeds, a differentiated candidate could create a scalable commercial opportunity from the company’s concentrated research platform.

Negative Factors

No demonstrated revenue baseZero reported revenue shows that CEL-SCI remains pre-commercial and has not yet demonstrated market acceptance or a repeatable sales engine. Until a product or service generates meaningful revenue, future growth depends primarily on successful development and commercialization rather than established operating demand.

Cel-Sci (LSR) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 24.27M
Dividend Yield: ―
Average Volume (3M): 324
Price to Earnings (P/E): -0.5
Beta (1Y): 2.02
Revenue Growth: ―
EPS Growth: 75.62%
Country: Germany
Employees: 43
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cel-Sci Business Overview & Revenue Model

Company Description

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the t...

Cel-Sci Risk Analysis

Cel-Sci disclosed 39 risk factors in its most recent earnings report. Cel-Sci reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Cel-Sci Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:LSR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATHE	41Neutral	$42.68M	-2.40	-48.25%	―	―	96.65%
UNCY	41Neutral	$104.18M	-2.23	-88.81%	―	―	43.63%
PLRX	37Underperform	$53.18M	-0.58	-53.22%	―	―	55.84%

* Healthcare Sector Average

Performance Comparison

DE:LSR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:LSR	Cel-sci	1.26	-5.29	-80.76%
ATHE	Alterity Therapeutics	2.16	-1.87	-46.40%
XBIT	XBiotech Inc.	1.88	-0.41	-17.90%
PLRX	Pliant Therapeutics, Inc.	0.86	-0.81	-48.62%
UNCY	Unicycive Therapeutics, Inc.	3.74	-0.70	-15.77%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cel-Sci AI Stock Analysis